Short answer · Medically reviewed summary · Last updated: 2026-05-08
Hyper-IgD Syndrome, also known as Hyperimmunoglobulinemia D with recurrent fever (HIDS), was first described in 1984 by Dutch pediatricians who observed a distinct pattern of periodic fevers and elevated IgD levels. Since then, the understanding of this rare autoinflammatory condition has evolved from a clinical observation into a well-defined genetic disorder caused by mutations in the MVK gene. How was Hyper-IgD Syndrome first discovered? The condition was first characterized in 1984 by Dr.
What is the history of Hyper-IgD Syndrome / Hyperimmunoglobulinemia D With Recurrent Fever (HIDS)?
History of Hyper-IgD Syndrome / Hyperimmunoglobulinemia D With Recurrent Fever (HIDS): when and how it was discovered, and the milestones in research since, medically reviewed.
Hyper-IgD Syndrome, also known as Hyperimmunoglobulinemia D with recurrent fever (HIDS), was first described in 1984 by Dutch pediatricians who observed a distinct pattern of periodic fevers and elevated IgD levels. Since then, the understanding of this rare autoinflammatory condition has evolved from a clinical observation into a well-defined genetic disorder caused by mutations in the MVK gene.
How was Hyper-IgD Syndrome first discovered?
The condition was first characterized in 1984 by Dr. J.W.M. van der Meer and colleagues, who identified a group of patients experiencing lifelong recurrent fevers accompanied by high serum immunoglobulin D (IgD) levels. Initially, the medical community struggled to categorize Hyper-IgD Syndrome, often misdiagnosing these patients with various rheumatological or infectious diseases due to the lack of clear diagnostic biomarkers beyond the elevated IgD levels.
How has our understanding of Hyper-IgD Syndrome evolved?
The most significant leap in our knowledge occurred in 1999, when researchers identified that Hyper-IgD Syndrome is caused by autosomal recessive mutations in the mevalonate kinase (MVK) gene. This discovery shifted the classification of the disease from a mysterious periodic fever syndrome to a metabolic disorder of the mevalonate pathway, which is essential for cholesterol and non-sterol isoprenoid biosynthesis.
What are the major milestones in managing this condition?
Management of Hyper-IgD Syndrome has shifted from symptomatic control to targeted biological therapy. Key milestones include:
- 1984: Initial clinical description of Hyper-IgD Syndrome symptoms.
- 1999: Identification of the MVK gene as the underlying genetic cause.
- 2000s-Present: The adoption of IL-1 inhibitors (such as anakinra or canakinumab) as a breakthrough therapy to block the inflammatory cascade.
How has patient advocacy changed the landscape?
For many years, patients with Hyper-IgD Syndrome felt isolated due to the rarity of the condition. Today, global initiatives and platforms like DiseaseMaps.org, where 6 community members have shared their experiences, allow patients to connect, share symptom management strategies, and accelerate awareness. This community-driven data is vital for clinicians to better understand the long-term prognosis of Hyper-IgD Syndrome.
Next steps
- Consult a clinical geneticist to confirm your MVK gene mutation status.
- Seek evaluation from a rheumatologist specializing in autoinflammatory diseases.
- Connect with the Hyper-IgD Syndrome community at DiseaseMaps.org to share experiences and find support.
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always consult with your healthcare provider regarding your specific medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Hyper-IgD syndrome.
- Orphanet: Mevalonate kinase deficiency (ORPHA:408).
- OMIM (Online Mendelian Inheritance in Man): Mevalonate Kinase Deficiency; MKD (#260920).
- PubMed: "Hyperimmunoglobulinemia D and periodic fever syndrome: a review" (van der Meer et al.).
